- Home
- AIRS vs KZIA Comparison
AIRS vs KZIA Comparison
Compare AIRS & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AIRS | KZIA |
|---|---|---|
| Founded | 2012 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.3M | 161.5M |
| IPO Year | 2021 | 1999 |
Fundamental Metrics
Financial Performance| Metric | AIRS | KZIA |
|---|---|---|
| Price | $2.67 | $9.86 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $3.75 | ★ $17.67 |
| AVG Volume (30 Days) | 1.2M | ★ 2.0M |
| Earning Date | 11-07-2025 | 12-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $157,554,000.00 | $1,199,108.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.78 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.53 | $2.86 |
| 52 Week High | $12.00 | $21.00 |
Technical Indicators
Market Signals| Indicator | AIRS | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 27.18 | 46.25 |
| Support Level | $2.69 | $11.75 |
| Resistance Level | $3.13 | $17.40 |
| Average True Range (ATR) | 0.33 | 2.77 |
| MACD | 0.11 | -0.23 |
| Stochastic Oscillator | 14.69 | 18.83 |
Price Performance
Historical ComparisonAbout AIRS AirSculpt Technologies Inc.
AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. Elite Body Sculpture, provides custom body contouring using the proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure. The company has one operating and reportable segment, direct medical procedure services.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.